Sign in to view content

Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen

Michael J Allingham, MD, PhD

Video
Published 2019

Michael J. Allingham, MD, PhD

AMD Non-neovscular Symposium

Related

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
Evaluation of Baseline Characteristics on Lesion Progression in a Large Phase 2 Clinical Trial for Geographic Atrophy (FILLY Study)
Eleonora Lad, MD, PhD
Annual Meeting Talks
2019
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated With Intravitreal Aflibercept or Ranibizumab in the VIEW studies
Robert L. Avery, MD
On Demand Cases, Courses, and Papers
2017

Category: AMD-Non-neovascular

See more